| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCULATIONAHA.105.591032 |
| P698 | PubMed publication ID | 16880329 |
| P50 | author | Johan Neyts | Q29460378 |
| Davy Vanhoutte | Q43228887 | ||
| Peter Carmeliet | Q2074300 | ||
| Frans Van de Werf | Q5492406 | ||
| P2093 | author name string | Andrew H Baker | |
| Stephane Heymans | |||
| Yigal M Pinto | |||
| Heinz-Peter Schultheiss | |||
| Matthias Pauschinger | |||
| Melissa Swinnen | |||
| Angela Kallwellis-Opara | |||
| Susanne Rutschow | |||
| Elisabeth Padalko | |||
| Fangye Gao | |||
| Armando De Palma | |||
| Raimund Torpai | |||
| P2860 | cites work | Thrombospondin-2 Is Essential for Myocardial Matrix Integrity: Increased Expression Identifies Failure-Prone Cardiac Hypertrophy | Q27987455 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 565-573 | |
| P577 | publication date | 2006-07-31 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis | |
| P478 | volume | 114 |
| Q35995215 | Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature |
| Q27486698 | Acute viral myocarditis |
| Q36202823 | Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. |
| Q34508351 | Animal models of cardiac disease and stem cell therapy |
| Q37091115 | Cardiac tissue factor: roles in physiology and fibrosis |
| Q38417041 | Coxsackievirus B3 replication and pathogenesis |
| Q47130215 | Dual Effects of Cell Free Supernatants from Lactobacillus acidophilus and Lactobacillus rhamnosus GG in Regulation of MMP-9 by Up-Regulating TIMP-1 and Down-Regulating CD147 in PMADifferentiated THP-1 Cells. |
| Q42205363 | Ectopic trypsin in the myocardium promotes dilated cardiomyopathy after influenza A virus infection |
| Q37824876 | Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases |
| Q33751633 | Enteroviruses as a possible cause of hypertension, dilated cardiomyopathy (DCM) and hypertensive heart failure (HHF) in South western Nigeria. |
| Q38423857 | Extracellular matrix communication and turnover in cardiac physiology and pathology |
| Q35005069 | IL-22-producing Th22 cells play a protective role in CVB3-induced chronic myocarditis and dilated cardiomyopathy by inhibiting myocardial fibrosis |
| Q36790142 | Imaging of matrix metalloproteinase activation and left ventricular remodeling |
| Q37591573 | Immunomodulation and matrix metalloproteinases in viral myocarditis |
| Q57584292 | Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis |
| Q39337854 | Induction of a broad spectrum of inflammation-related genes by Coxsackievirus B3 requires Interleukin-1 signaling |
| Q41208579 | Liver X receptor activation enhances CVB3 viral replication during myocarditis by stimulating lipogenesis. |
| Q97548126 | Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis |
| Q64916705 | Myocarditis in Humans and in Experimental Animal Models. |
| Q37964006 | Novel effects of macrolide antibiotics on cardiovascular diseases |
| Q33811045 | Quantification of myocardial fibrosis by digital image analysis and interactive stereology. |
| Q38180743 | Regulation of the immune response during infectious myocarditis. |
| Q36773152 | Rodent models of heart failure |
| Q37996857 | Rodent models of heart failure: an updated review. |
| Q28478101 | Role of surface chemistry in protein remodeling at the cell-material interface |
| Q34808730 | Sizing up models of heart failure: Proteomics from flies to humans. |
| Q37607436 | TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'. |
| Q38174997 | Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis |
| Q51770077 | The development of cardiac fibrosis in low tissue factor mice is gender-dependent and is associated with differential regulation of urokinase plasminogen activator. |
| Q42282000 | The investigation of the possible relationship between Coxsackie viruses and pemphigus. |
| Q35152813 | The role of 1.5 tesla MRI and anesthetic regimen concerning cardiac analysis in mice with cardiomyopathy |
| Q44966244 | The role of viral infections in the development of dilated cardiomyopathy. |
| Q56898176 | Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells |
| Q41825669 | Tissue inhibitor of metalloproteinase-1 and -3 improves cardiac function in an ischemic cardiomyopathy model rat. |
| Q36454235 | Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats |
| Q39630609 | Up-regulation of ectopic trypsins in the myocardium by influenza A virus infection triggers acute myocarditis |
| Q35124141 | Urokinase and its receptors in chronic kidney disease. |
| Q34639045 | Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages |
| Q37543413 | Viral myocarditis: diagnosis, aetiology and management |
| Q38052447 | Viral myocarditis: from experimental models to molecular diagnosis in patients |
| Q35180538 | Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts |
Search more.